Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elutia (ELUT) Current Deferred Revenue (2019 - 2021)

Elutia recorded quarterly Current Deferred Revenue of $5000.0 in Q4 2021, down 95.45% quarter-over-quarter from $110000.0 in Q3 2021, and down 99.06% year-over-year from $533000.0 in Q4 2020.

Elutia's Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $5000.0 for Q4 2021.

  • In Q4 2021, Current Deferred Revenue fell 99.06% year-over-year to $5000.0; the TTM figure through Dec 2021 stood at $5000.0 (down 99.06% YoY), while the FY2021 annual figure was $5000.0, down 99.06% from the prior year.
  • Current Deferred Revenue came in at $5000.0 for Q4 2021 at Elutia, down from $110000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $650000.0 in Q4 2019 to a low of $5000.0 in Q4 2021.
  • A 3-year average of $354000.0 and a median of $392000.0 in 2021 frame the typical range for Current Deferred Revenue.
  • Across the five-year window, Current Deferred Revenue retreated 18.0% in 2020 and sank 99.06% in 2021, its largest moves.
  • Elutia's Current Deferred Revenue stood at $650000.0 in 2019, then slipped by 18.0% to $533000.0 in 2020, then tumbled by 99.06% to $5000.0 in 2021.
  • According to Business Quant data, Current Deferred Revenue over the past three periods registered $5000.0, $110000.0, and $251000.0 for Q4 2021, Q3 2021, and Q2 2021 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Elutia 45.79 Mn 17.31 Mn 1.80 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 5,000.00
Sep 30, 2021 110,000.00
Jun 30, 2021 251,000.00
Mar 31, 2021 392,000.00
Dec 31, 2020 533,000.00
Sep 30, 2020 537,000.00
Dec 31, 2019 650,000.00